Systematic Coronary Risk Evaluation 2—Older Persons (SCORE2-OP) is a set of sex-specific risk equations developed for European cardiovascular prevention practice in adults aged 70 to 89 years. It extends the SCORE2 framework so that primary prevention discussions in older populations can use an explicit, transparent estimate of 10-year risk of fatal and non-fatal atherosclerotic cardiovascular disease (CVD), rather than extrapolating inappropriately from models designed for middle-aged cohorts.
Why a separate model for older persons
Cardiovascular risk changes markedly with age: incidence rises, competing causes of death become more common, and the balance between treatment benefit and harm depends strongly on baseline risk and life expectancy. The original SCORE2 algorithms were developed for ages roughly 40–69 years. Applying those same functional forms and centring to people in their seventies and eighties without adaptation can misrepresent both absolute risk and the way risk factors act at advanced ages.
SCORE2-OP was therefore derived as a competing-risk–aware extension, with predictors and interactions appropriate to older age groups, and with recalibration to reflect how CVD rates and risk factor distributions differ across European regions. The result is a tool that aligns with ESC prevention logic: communicate absolute risk, place the individual within guideline risk strata where applicable, and support shared decision-making about lifestyle and preventive pharmacotherapy in context.
Outcome and time horizon
The SCORE2-OP models target 10-year cumulative incidence of fatal and non-fatal atherosclerotic CVD (in line with the broader SCORE2 family). This endpoint is chosen to match how European prevention guidelines frame lipid-lowering, blood pressure management, and antithrombotic decisions in primary prevention—namely as decisions about medium-term absolute risk reduction in people without established clinical CVD, subject to individual circumstances and guideline thresholds.
Intended population
SCORE2-OP is intended for people who resemble the derivation and validation cohorts used in its development:
- Age 70–89 years at the time of assessment.
- No prior clinical atherosclerotic CVD (it is a primary prevention risk tool, not for secondary prevention).
- People in whom a European region–based calibration is clinically meaningful (see below).
Type 2 diabetes mellitus is included as a predictor in the published SCORE2-OP equations. That distinguishes SCORE2-OP from the standard SCORE2 tool for middle age, where diabetes lies outside the intended target population and separate SCORE2-Diabetes models apply to younger adults with type 2 diabetes. In practice, clinicians still integrate glycaemic control, renal function, duration of disease, and frailty when interpreting any single risk number in older patients with diabetes.
Required inputs
The calculator combines the following variables:
- Age (years)—entered as the patient’s current age within the validated band.
- Sex at birth (male / female)—separate coefficients are used for each.
- Geographical risk region—one of four ESC-aligned categories (low, moderate, high, very high CVD mortality), which adjusts the final risk to regional epidemiology.
- Current smoking (yes / no).
- Type 2 diabetes mellitus (yes / no).
- Systolic blood pressure (mmHg).
- Total cholesterol and HDL cholesterol—typically entered in mmol/L; mg/dL values can be converted using the conventional factor used in clinical software.
Each continuous predictor is centred in the model (for example, age relative to a reference such as 73 years, systolic pressure relative to 150 mmHg, lipids relative to published anchor values). That centring keeps the linear predictor numerically stable and reflects how the model was fitted; it does not change the interpretation that higher SBP, higher total cholesterol, lower HDL, smoking, and diabetes increase predicted risk, all else equal.
How the estimate is produced (conceptually)
Computation follows the same broad pattern as SCORE2:
- A linear predictor is built from the risk factors above, including age interaction terms so that the effect of smoking, diabetes, blood pressure, and lipids can vary appropriately across older age.
- That linear predictor is transformed into an intermediate baseline cumulative risk using sex-specific survival parameters published with the model.
- A two-step calibration maps that intermediate risk to the region-specific 10-year risk using scale parameters that depend on sex and the chosen geographical risk region. This step is what allows the same underlying equation to reflect lower or higher background CVD rates in different parts of Europe.
- The final risk is expressed as a percentage, usually rounded to one decimal place to match widely distributed charts and electronic tools.
Risk categories (age ≥ 70 years)
For people aged 70 and over, ESC-oriented materials often stratify 10-year fatal and non-fatal CVD risk into three bands. The following table summarises the thresholds used alongside SCORE2-OP in many educational implementations:
| Category | 10-year risk |
|---|---|
| Low | Below 7.5% |
| Moderate | 7.5% to below 15% |
| High | 15% or higher |
Exact guideline thresholds and treatment recommendations evolve with national guidance and comorbidity; the category label should always be read together with frailty, polypharmacy, patient preferences, and local protocols.
Relationship to SCORE2 and SCORE2-Diabetes
SCORE2 (ages roughly 40–69, without type 2 diabetes in the intended use case) and SCORE2-OP (ages 70–89) share the same philosophical approach—competing-risk adjustment and regional recalibration—but use different functional forms and centring because the age structure of risk differs. SCORE2-Diabetes addresses type 2 diabetes in the younger adult range with additional variables such as glycaemic control and kidney function; it is not simply interchangeable with SCORE2-OP for every older patient with diabetes. Choice of tool should follow the validated age range and the clinical question being asked.
Strengths and limitations
Strengths include transparency of inputs, alignment with European prevention framing, external validation across multiple populations reported in the original work, and integration with the same four-region calibration scheme used elsewhere in the SCORE2 family—supporting consistent messaging for patients who cross age bands over time.
Limitations include the usual constraints of derivation cohorts: under-representation of some ethnicities and health states, uncertainty in frailty and multimorbidity not fully captured by a short variable set, and the fact that a single 10-year percentage cannot encode quality of life, bleeding risk, or treatment adherence. SCORE2-OP is not validated for established cardiovascular disease, severe target-organ damage in the sense of secondary prevention, or settings where non-European calibration is required. Laboratory and blood pressure values should reflect stable, clinically representative measurements rather than single casual readings when possible.
Using this calculator responsibly
The SCORE2-OP calculator on this site is an educational aid. It does not establish a diagnosis, dictate therapy, or replace judgment by a qualified clinician. Medication decisions in older adults should consider blood pressure variability, orthostasis, renal function, drug interactions, cognitive status, and goals of care. Always interpret the output in light of current ESC and national guidance, and document shared decision-making when preventive drugs are started, intensified, or de-prescribed.